ProQR Therapeutics
543 Bryant Street
Palo Alto
California
94301
United States
Website: https://proqr-tx.com/
Email: info@proqr-tx.com
About ProQR Therapeutics
We are ProQR, a biotechnology company dedicated to changing lives by developing RNA therapies for rare genetic diseases. We focus our drug development mainly on a group of blinding disorders affecting the retina, called inherited retinal diseases.
139 articles about ProQR Therapeutics
-
ProQR Receives Orphan Drug Designation From EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
11/29/2017
DEB is a rare genetic disease that can lead to severe blistering of the skin resulting in high treatment burden and poor quality of life for patients.
-
ProQR Announces Results for the Third Quarter of 2017
11/20/2017
Runway into the second half of 2019: cash of €39.7 million at end of Q3.
-
ProQR Prices Approximately $20M Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares
11/14/2017
In addition, in the public offering, ProQR has granted the underwriters a 30-day option to purchase up to 745,471 additional ordinary shares at the public offering price, less underwriting discounts and commissions.
-
ProQR Announces Proposed Public Offering of Ordinary Shares
11/14/2017
ProQR expects to grant the underwriters a 30-day option to purchase additional ordinary shares, on the same terms and conditions.
-
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
11/13/2017
The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial in children and adults with Leber’s congenital amaurosis 10.
-
ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board
11/9/2017
Dr. Thaddeus (Ted) Dryja is a pioneer in the field of retinal genetic diseases.
-
ProQR Announces Management Change and Key Promotions
10/26/2017
The company's CMO will leave, effective November 4, 2017 to pursue a new opportunity.
-
ProQR Therapeutics Jumps As CF Drug Impresses In Early Stage Trial
9/26/2017
-
ProQR Therapeutics Presents In Vivo Proof Of Concept Data For The Axiomer RNA Editing Platform Technology
9/21/2017
-
ProQR Therapeutics Receives Orphan Drug Designation From FDA For Drug Candidate QR-313 For Dystrophic Epidermolysis Bullosa And Will Present Data At Two Scientific Conferences
9/19/2017
-
ProQR Therapeutics Spins Out CNS-Focused Biotech, Amylon Therapeutics
9/12/2017
-
ProQR Therapeutics’s Drug Candidate QRX-421 For Usher Syndrome Receives Orphan Drug Designation From FDA And EMA
9/5/2017
-
ProQR Therapeutics Completes Dosing Of Cystic Fibrosis Patients In QR-010 Phase Ib Trial
8/29/2017
-
ProQR Therapeutics Strengthens Its Scientific Advisory Board With The Appointment Of Dr. Phil Zamore, Dr. Cy Stein And Dr. Scott Armstrong
8/28/2017
-
ProQR Therapeutics Announces Results For The Second Quarter Of 2017
8/16/2017
-
ProQR Therapeutics B.V.’s Drug Candidate QRX-411 For Usher Syndrome Receives Orphan Drug Designation From FDA And EMA
7/5/2017
-
ProQR Therapeutics B.V. R&D Day Highlights Progress On Pipeline And Introduces Axiomer, A Novel Proprietary RNA Technology
6/15/2017
-
ProQR Therapeutics B.V. To Present QR-010 Data At The European Cystic Fibrosis Society Conference And Provides An Update On The Ongoing Phase Ib Trial
6/8/2017
-
ProQR Therapeutics B.V. Receives Fast Track Designation From The FDA For QR-110 For Leber’s Congenital Amaurosis Type 10
5/31/2017
-
ProQR Therapeutics B.V. Announces Results For The First Quarter Of 2017
5/17/2017